L
Louise Provencher
Researcher at Laval University
Publications - 111
Citations - 6329
Louise Provencher is an academic researcher from Laval University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 34, co-authored 106 publications receiving 5697 citations. Previous affiliations of Louise Provencher include Faculté de médecine – Université de Sherbrooke & Université du Québec.
Papers
More filters
Journal ArticleDOI
Adjuvant docetaxel for node-positive breast cancer.
Miguel Martin,Tadeusz Pienkowski,John R. Mackey,M. Pawlicki,Jean-Paul Guastalla,Charles Weaver,Eva Tomiak,T. Al-Tweigeri,Linnea Chap,Eva Juhos,Raymond Guevin,Anthony Howell,Tommy Fornander,John D. Hainsworth,Robert E. Coleman,Jefferson Vinholes,Manuel Modiano,Tamás Pintér,Shou C. Tang,Bruce Colwell,Catherine Prady,Louise Provencher,David Walde,Álvaro Rodríguez-Lescure,Judith Hugh,Camille Loret,Matthieu Rupin,Sandra Blitz,Philip Jacobs,Michael Murawsky,Alessandro Riva,Charles L. Vogel +31 more
TL;DR: Adjuvant chemotherapy with TAC, as compared with FAC, significantly improves the rates of disease-free and overall survival among women with operable node-positive breast cancer.
Journal ArticleDOI
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
David Miles,Arlene Chan,Luc Dirix,Javier Cortes,Xavier Pivot,Piotr Tomczak,Thierry Delozier,Joohyuk Sohn,Louise Provencher,Fabio Puglisi,Nadia Harbeck,Guenther G. Steger,Andreas Schneeweiss,Andrew M Wardley,Andreas Chlistalla,Gilles Romieu +15 more
TL;DR: Bvacizumab 15 mg/kg every 3 weeks significantly increased PFS when combined with docetaxel as first-line therapy for MBC compared with docentaxel plus placebo and had limited impact on the known toxicity profile of docetAXel.
Journal ArticleDOI
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
Martine Piccart,Gabriel N. Hortobagyi,Mario Campone,Kathleen I. Pritchard,Fabienne Lebrun,Yoshinori Ito,Shinzaburo Noguchi,Alejandra T. Perez,Hope S. Rugo,Ines Deleu,Howard A. Burris,Louise Provencher,Patrick Neven,M. Gnant,Mikhail Shtivelband,C. Wu,Jenna Fan,Wentao Feng,Tetiana Taran,José Baselga +19 more
TL;DR: In BOLERO-2, adding EVE to EXE did not confer a statistically significant improvement in the secondary end point OS despite producing a clinically meaningful and statistically significant improved in the primary end point, PFS.
Journal ArticleDOI
Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review.
TL;DR: The aim of this review is to describe the effects of alopecia on quality of life (QOL) in this population of breast cancer patients.
Journal ArticleDOI
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
Lee S. Rosen,D. Gordon,William Dugan,Pierre Major,Peter D. Eisenberg,Louise Provencher,Mary Kaminski,Joe Simeone,John J. Seaman,Bee-Lian Chen,Robert E. Coleman +10 more
TL;DR: Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial.